An enzymatic assay for quantification of inositol in human term placental tissue.

A modified sensitive, cheap and simple enzymatic assay method is described for the quantitation of inositol (6-carbon polyol) in human placental tissue. Water-soluble and total (water-soluble and lipid-bound) inositol isomers were extracted and quantified using a 96-well adaptation of the Megazyme® assay. This assay specifically recognized myo-inositol (predominant isomer), d-chiro-, epi-, and allo-inositols, but not scyllo-inositol, glucose or fucose. In term placenta, water-soluble and total inositol contents were high [489 (±58) and 635 (±69) µg/g respectively], and reliably quantified with good reproducibility. This modified assay could facilitate placental inositol biology research, particularly pertinent now with interest in myo-inositol supplementation for gestational diabetes (GDM) prevention.

Myo-inositol alters 13C-labeled fatty acid metabolism in human placental explants.

We postulate that myo-inositol, a proposed intervention for gestational-diabetes, affects transplacental lipid supply to the fetus. We investigated the effect of myo-inositol on fatty-acid processing in human placental-explants from uncomplicated pregnancies. Explants were incubated with 13C-labeled palmitic-acid, 13C-oleic-acid and 13C-docosahexaenoic-acid across a range of myo-inositol concentrations for 24 h and 48 h. The incorporation of labeled-fatty-acids into individual lipids was quantified by liquid-chromatography-mass-spectrometry. At 24 h, myo-inositol increased the amount of 13C-palmitic-acid and 13C-oleic-acid labeled lipids (median fold-change relative to control=1). Significant effects were seen with 30 µM myo-inositol (physiological) for 13C-palmitic-acid-lysophosphatidylcholines (1.26) and 13C-palmitic-acid-phosphatidylethanolamines (1.17). At 48 h, myo-inositol addition increased 13C-oleic-acid-lipids but decreased 13C-palmitic-acid and 13C-docosahexaenoic-acid lipids. Significant effects were seen with 30 µM myo-inositol for 13C-oleic-acid-phosphatidylcholines (1.25), 13C-oleic-acid-phosphatidylethanolamines (1.37) and 13C-oleic-acid-triacylglycerols (1.32) and with 100 µM myo-inositol for 13C-docosahexaenoic-acid-triacylglycerols (0.78). Lipids labeled with the same 13C-fatty-acid showed similar responses when tested at the same time-point, suggesting myo-inositol alters upstream processes such as fatty-acid uptake or activation. Myo-inositol supplementation may alter placental lipid physiology with unknown clinical consequences.